METHOD FOR PREPARING MODIFIED POLYPEPTIDES

Methods for producing polypeptide with altered immunogenicity or improved stability properties are disclosed. The methods involve 124.-. (canceled)25. A method for altering the immunogenicity and/or increasing the functional in vivo half-life of a polypeptide of interest , which method comprises(a) selecting a region of the polypeptide of interest involved in or otherwise responsible for the immunogenicity and/or the functional in vivo half-life of the polypeptide,(b) diversifying the selected region so as to produce a diversified population of nucleotide sequences encoding the polypeptide of interest,(c) expressing the diversified population of nucleotide sequences obtained in step (b) in a glycosylating host cell,(d) screening polypeptides expressed in step (c) for function, immunogenicity and/or functional in vivo half-life,(e) selecting functional polypeptides having altered immunogenicity or increased functional in vivo half-life as compared to the polypeptide of interest, and(f) optionally subjecting the nucleotide sequence encoding the polypeptide selected in step (e) to one or more repeated cycles of steps (a)-(e),wherein the selected polypeptides have an altered glycosylation pattern relative to the polypeptide of interest.26. A method for altering the immunogenicity and/or increasing the functional in vivo half-life of a polypeptide of interest , which method comprises(a) selecting a region of the polypeptide of interest involved in or otherwise responsible for the immunogenicity and/or the functional in vivo half-life of the polypeptide,(b) diversifying the selected region so as to produce a diversified population of nucleotide sequences encoding the polypeptide of interest,(c) expressing the diversified population of nucleotide sequences obtained in step (b),(d) screening polypeptides expressed in step (c) for function, immunogenicity and/or functional in vivo half-life,(e) selecting functional polypeptides having altered immunogenicity or increased ...

Factor VII or VIIa - Like Molecules

Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided. 167-. (canceled)68. A nucleotide sequence encoding a polypeptide having an amino acid sequence which differs from that of wild-type FVII or FVIIa shown in SEQ ID NO:1 in that at least one amino acid residue comprising an attachment group for a non-polypeptide moiety has been introduced or removed.69. An expression vector harbouring the nucleotide sequence of .70. A host cell comprising a nucleotide sequence of or an expression vector according to .71. The host cell according to claim 70 , wherein the host cell is a gammacarboxylating cell capable of in vivo glycosylation. The present application claims priority to and benefit of the following United States and international patent applications: Danish Patent Application Number PA 2000 00218, filed Feb. 11, 2000; U.S. Provisional Patent Application No. 60/184,036, filed Feb. 22, 2000; and, U.S. Provisional Patent Application No. 60/241,916, filed Oct. 18, 2000.Pursuant to 37 C.F.R. 1.71(e), Applicants note that a portion of this disclosure contains material which is subject to copyright protection. The copyright owner has no objection to the facsimile reproduction by anyone of the patent document or patent disclosure, as it appears in the Patent and Trademark Office patent file or records, but otherwise reserves all copyright rights whatsoever.The present invention relates to novel Factor VII (FVII) or Factor VIIa (FVIIa) polypeptide conjugates, to their preparation and use in therapy, in particular for the treatment of a variety of coagulation-related disorders.Blood coagulation is a process consisting of a complex interaction of various blood components (or factors) that eventually gives rise to a fibrin clot. Generally, the blood ...

Novel carbamylated epo and method for its production

The present invention discloses a method for production of novel carbamylated erythropoietin and compositions comprising the novel carbamylated erythropoietin and pharmaceutical compositions comprising this and uses thereof.

PRINTED WIRING BOARD ASSEMBLY AND RELATED METHODS

A method is for making a printed wiring board (PWB) assembly. The method may include forming a first PWB having a plurality of first electrically conductive pads, forming a second PWB including a plurality of electrically conductive traces having exposed ends on an edge surface of the second PWB, and covering the edge surface of the second PWB with an electrically conductive layer. The method may also include selectively removing portions of the electrically conductive layer to define a plurality of second electrically conductive pads electrically connected to corresponding ones of the exposed ends of the electrically conductive traces, and assembling the first and second PWBs together so that the first and second electrically conductive pads are electrically coupled together to define the PWB assembly. 121-. (canceled)22. A printed wiring board (PWB) assembly comprising:a first PWB comprising a plurality of first electrically conductive pads; and 'a plurality of internal electrically conductive traces having exposed ends on an edge surface of the second PWB, each internal electrically conductive trace having a width increasing as each internal electrically conductive trace approaches the edge surface, and', 'a second PWB comprising'}a plurality of second electrically conductive pads on the edge surface and electrically connected to corresponding ones of the exposed ends;said first and second PWBs assembled together so that said plurality of first electrically conductive pads are electrically coupled with respective ones of said plurality of second electrically conductive pads.23. The PWB assembly according to wherein the edge surface of the second PWB has a planar shape.24. The PWB assembly according to wherein said second PWB comprises a multi-layer PWB.25. The PWB assembly according to wherein said plurality of first electrically conductive pads are on a major surface of said first PWB so that said first and second PWBs are transverse to one another.26. The PWB ...

CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS FOR PROLONGED EFFECT

Layered pharmaceutical composition suitable for oral use in the treatment of diseases where absorption takes place over a large part of the gastrointestinal tract. The composition comprising A) a solid inner layer comprising 128-. (canceled)29. A layered pharmaceutical composition for controlled release of an active substance , comprising:a solid inner layer (A) comprising the active substance and a disintegrant, the solid inner layer (A) being positioned between two outer layers (B1) and (B2),each outer layer (B1) and (B2) comprising a polymer selected from the group consisting of (i) substantially water soluble or crystalline polyglycol homopolymers having a molecular weight (MW) of about 100,000 daltons or greater and (ii) substantially water soluble or crystalline polyglycol copolymers having a MW of about 2,000 daltons or greater, and mixtures thereof, wherein each outer layer is free of the disintegrant and optionally further comprises a second active substance, anda coating (C) forming a shell covering the solid inner layer (A) and partially covering outer layers (B1) and (B2) with two openings exposing a surface of each outer layer (B1) and (B2), wherein the coating (C) comprises a polymer and is substantially insoluble in and impermeable to gastrointestinal fluids;wherein the solid inner layer (A), without the outer layers (B1) and (B2) and the coating (C), disintegrates within 60 minutes when subjected to disintegrating test according to the Eur. Ph.30. The pharmaceutical composition of claim 29 , wherein the active substance in the solid inner layer (A) is present in the form of a multiple unit formulation.31. The pharmaceutical composition of claim 30 , wherein the multiple unit formulation is a controlled release multiple unit formulation.32. The pharmaceutical composition of claim 30 , wherein the active substance of the solid inner layer (A) is present in a form selected from pellets claim 30 , beads claim 30 , flakes claim 30 , mini-tablets claim 30 ...

VALVE ARRANGEMENT AND DIAPHRAGM ASSEMBLY FOR A VALVE ARRANGEMENT

The present invention relates to a valve arrangement () comprising a valve housing (), a valve inlet (), a valve outlet () and a diaphragm assembly for controlling a fluid flow through the valve housing () from the valve inlet () to the valve outlet (), the diaphragm assembly comprising a diaphragm () and a diaphragm plate () at least partially covering the diaphragm (), the diaphragm () comprising one or more equalization holes () passing through the diaphragm () and the diaphragm plate () comprising one or more equalization openings () passing through the diaphragm plate (), the equalization holes () being aligned with the equalization openings (). According to the invention, the diaphragm assembly comprises an engagement zone engaging the diaphragm () in order to rotationally fix the diaphragm () and the diaphragm plate () with respect to each other. This has the effect that the equalization holes () will keep aligned with the equalization openings (). Thus, proper function of the valve arrangement () is ensured at all times. Furthermore, the invention relates to a diaphragm assembly for a valve arrangement () as described above. 1. A valve arrangement comprising a valve housing , a valve inlet , a valve outlet , and a diaphragm assembly for controlling a fluid flow through the valve housing from the valve inlet to the valve outlet , the diaphragm assembly comprising a diaphragm and a diaphragm plate at least partially covering the diaphragm , the diaphragm comprising one or more equalization holes passing through the diaphragm and the diaphragm plate comprising one or more equalization openings passing through the diaphragm plate , the equalization holes being aligned with the equalization openings , wherein the diaphragm assembly comprises an engagement zone engaging the diaphragm in order to rotationally fix the diaphragm and the diaphragm plate with respect to each other.2. The valve arrangement according to claim 1 , wherein the engagement zone radially ...

AIR CURTAIN SYSTEMS AND METHODS FOR VEHICLE CABINS

A system includes an outflow vent that has a cap releasably mounted to a panel within an internal cabin of a vehicle. The cap is elongated from a first end of the cap to a second end of the cap opposite the first end. The cap has a base wall that is overlaid on the panel and defines at least one slot therethrough. The cap receives an airflow generated by an airflow generator, and the at least one slot emits the airflow from the cap to form an air curtain within the internal cabin.

Amorphous form of 5-bromopyridin-3-yl 3-deoxy-3-[4-(3,4,5-trifluorophenyl)-1h-1,2,3-triazol-1-yl]-1-thio-alpha-d-galactopyranoside

A stabilized amorphous form of a compound of formula I as well as compositions for oral administration including the compound of formula I in a therapeutically effective amount. Also, methods for treatment of a disease or disorder in which therapeutically effective amount of a composition including a compound of formula I is administered to a subject in need thereof.

SYSTEMS, DEVICES, AND METHODS FOR EXTENDABLE CONVEYORS

Systems, devices, methods and computer program products for extendable conveyors are provided. A system includes an extendable conveyor and a separation module. The extendable conveyor is operable to convey items from an upstream side of the extendable conveyor to a downstream side of the extendable conveyor. Further, it is configured to increase the distance from the upstream side to the downstream side. The separation module is operable for conveying items towards the extendable conveyor and configured to decelerate the conveying of the items on the separation module. 1. A conveying system comprising:an extendable conveyor, operable to convey items from an upstream side of the extendable conveyor to a downstream side of the extendable conveyor, and configured to increase the distance from the upstream side to the downstream side,a separation module, operable for conveying items towards the extendable conveyor and configured to decelerate the conveying of the items on the separation module wherein the separation module is configured to be positioned relative to the extendable conveyor with a level difference between a conveying surface of the separation module and a conveying surface of the extendable conveyor at its upstream side wherein by decreasing the conveying speed, a deceleration of the items is achieved, and an impulse is imparted on the items, such that a pile of items is separated into single pieces, wherein the item which is the top- and front-most item of the pile falls onto the extendable conveyor.2. The system according to claim 1 , wherein the separation module is configured to convey the items at variable speeds.3. The system according to claim 1 , wherein the separation module is configured to decelerate the conveying of the items fully to a halt.4. The system according to claim 1 , wherein the separation module is configured to convey items at least at a first speed and a second speed claim 1 , the first speed being smaller than the second speed ...

Catalyst Ceramic Candle Filter for Combined Particulate Removal and the Selective Catalytic Reduction (SCR) of Nitrogen-Oxides

The present invention pertains to a catalyst for use in the selective catalytic reduction (SCR) of nitrogen oxides cornprising: —a ceramic candle filter substrate and—a coating which comprises an oxidic metal carrier comprising an oxide of titanium and a catalytic metal oxide which comprises an oxide of vanadium wherein the mass ratio vanadium/titanium is 0.03 to 0.27, —wherein the mass ratio is calculated based on the mass of vanadium metal and titanium metal, and—wherein the catalyst comprises from about 1 to about 10% by weight of the catalytically active material, and—wherein the catalytic metal oxide is adsorbed onto the surface of the oxidic metal carrier. 1. A catalyst for use in the selective catalytic reduction (SCR) of nitrogen oxides comprisinga ceramic candle filter substrate anda coating which comprises an oxidic metal carrier comprising an oxide of titanium and a catalytic metal oxide which comprises an oxide of vanadium wherein the mass ratio vanadium/titanium is 0.03 to 0.27,wherein the mass ratio is calculated based on the mass of vanadium metal and titanium metal, andwherein the catalyst comprises from 1 to 20% by weight of the catalytically active material, andwherein the catalytic metal oxide is adsorbed onto the surface of the oxidic metal carrier.2. The catalyst according to claim 1 , wherein the catalytic metal oxide of the coating which comprises an oxide of vanadium comprises vanadium pentoxide (VO).3. The catalyst according to claim 2 , wherein the catalytic metal oxide of the coating which comprises an oxide of vanadium comprises in addition an oxide of tungsten and/or molybdenum and/or antimony.4. The catalyst according to claim 1 , wherein the oxidic metal carrier of the coating which comprises an oxide of titanium comprises titanium dioxide.5. The catalyst according to claim 4 , wherein the oxidic metal carrier of the coating which comprises an oxide of titanium further comprises an oxide of aluminum claim 4 , cerium claim 4 , zirconium ...

POLYMORPHIC FORMS AND PROCESS

The present invention relates to a polymorph of a compound of formula (I) 2. The polymorph of claim 1 , wherein the polymorph is a hydrate.3. The polymorph of claim 2 , wherein the hydrate contains 3-5% by weight water.4. The polymorph of claim 1 , wherein the polymorph is micronized.5. The polymorph of claim 4 , wherein the polymorph is micronized to a size that can reach the bronchioles and/or the alveoli of the human.6. A pharmaceutical composition comprising the polymorph of claim 1 , and optionally a pharmaceutically acceptable additive.7. A process of making the polymorph of comprising:suspending or dissolving 3,3′-Dideoxy-3,3′-bis-[4-(3-fluorophenyl)-1H-1,2,3-triazol-1-yl]-1,1′-sulfanediyl-di-β-D-galactopyranoside in an organic solvent; and thenmaking polymorphic form 1 by temperature cycling, crash cooling, evaporation, or a combination thereof.8. A method for treatment of pulmonary fibrosis in a human comprising administering to the lung tissue of the human an amount of the polymorph of effective to treat said pulmonary fibrosis.9. The method of claim 8 , wherein the administration is carried out by a dry powder inhaler.10. The method of claim 9 , wherein the administration is carried out by a monodose dry powder inhaler.11. The method of claim 8 , wherein the polymorph is administered to the bronchioles and/or the alveoli of the human.12. The method of claim 8 , wherein the amount is a once daily amount from 0.15 mg to 50 mg.13. The method of claim 12 , wherein the amount is a once daily amount selected from the group consisting of: 0.15 mg to 0.50 mg claim 12 , 0.50 mg to 0.75 mg claim 12 , 0.75 mg to 1.25 mg claim 12 , 1.25 mg to 1.5 mg claim 12 , 1.5 mg to 1.75 mg claim 12 , 1.75 mg to 2 mg claim 12 , 2 mg to 2.25 mg claim 12 , 2.25 mg to 2.5 mg claim 12 , 2.5 mg to 2.75 mg claim 12 , 2.75 mg to 3 mg claim 12 , 3 mg to 5 mg claim 12 , 5 mg to 7 mg claim 12 , 7 mg to 8 mg claim 12 , 8 mg to 10 mg claim 12 , 10 mg to 20 mg and 20 mg to 50 mg.14. A method ...

ONCE-DAILY TREATMENT OF PULMONARY FIBROSIS

The present invention relates to a compound of formula (I) for use in a method for treatment of pulmonary fibrosis in a human including administering once-a-day to the narrowest parts of the lung tissue of the human an amount of the compound of formula (I) effective to treat said pulmonary fibrosis. 123-. (canceled)25. The compound of claim 24 , wherein the pulmonary fibrosis is Idiopathic pulmonary fibrosis (IPF).26. The compound of claim 24 , wherein the administration is carried out by a dry powder inhaler.27. The compound of claim 24 , wherein the administration is carried out by a monodose dry powder inhaler.28. The compound of claim 24 , wherein the once daily amount is from 0.15 mg to 50 mg.29. The compound of claim 24 , further comprising:a pharmaceutically acceptable additive.31. The method of claim 30 , wherein the compound of formula (I) is bis (3-deoxy-3-(3-fluorophenyl-1H-1 claim 30 ,2 claim 30 ,3-triazol-1-yl)-β-D-galactopyranosyl)-sulfane as the free form.32. The method of claim 30 , wherein the pulmonary fibrosis is Idiopathic pulmonary fibrosis (IPF).33. The method of claim 30 , wherein the administration is carried out by a dry powder inhaler.34. The method of claim 30 , wherein the administration is carried out by a monodose dry powder inhaler.35. The method of claim 30 , wherein the narrowest parts of the lung tissue are the bronchioles and the alveoli.36. The method of claim 30 , wherein the once daily amount is from 0.15 mg to 50 mg.38. The dry powder inhaler device of claim 37 , wherein the compound of formula (I) is bis (3 -deoxy-3 -(3 -fluorophenyl- 1H-1 claim 37 ,2 claim 37 ,3-triazol-1-yl)-β-D-galactopyranosyl) sulfane as the free form.39. The dry powder inhaler device of claim 37 , wherein the pulmonary fibrosis is Idiopathic pulmonary fibrosis (IPF).40. The dry powder inhaler device of claim 37 , which is a monodose dry powder inhaler.41: The dry powder inhaler device of claim 37 , wherein the amount is from 0.15 mg to 50 mg.42. The dry ...

SOLENOID VALVE

The invention relates to a solenoid valve with a housing as well as an inlet and an outlet, wherein the solenoid valve further comprises a valve element and an orifice, wherein the orifice comprises an orifice inlet and an orifice outlet. In order to increase the maximum operating pressure differential of the solenoid valve the orifice is provided in a membrane and the orifice has a diffuser characteristic in a direction from the orifice inlet to the orifice outlet. 115-. (canceled)16. A solenoid valve comprising a housing having an inlet and an outlet , wherein the solenoid valve further comprises a valve element and an orifice , wherein the orifice comprises an orifice inlet and an orifice outlet , and the orifice is provided in a membrane , and wherein the orifice has a diffuser characteristic in a direction from the orifice inlet to the orifice outlet , wherein the orifice comprises at least one conical orifice section , wherein the conical orifice section extends over most of length L of the orifice.17. The solenoid valve according to claim 16 , wherein walls of the conical orifice section are inclined relative to a central axis of the orifice by an angle of less than 10°.18. The solenoid valve according to claim 16 , wherein the cross-sectional area of the orifice inlet is smaller than the cross-sectional area of the orifice outlet.19. The solenoid valve according to claim 16 , wherein the walls of the conical orifice section are inclined relative to the central axis of the orifice by an angle of more than 2.5°.20. The solenoid valve according to claim 16 , wherein the orifice comprises at least one cylindrical orifice section.21. The solenoid valve according to claim 16 , wherein the orifice comprises at least one conical outlet section.22. The solenoid valve according to claim 16 , wherein the orifice is provided in an orifice member.23. The solenoid valve according to claim 16 , wherein the orifice is an integral part of a membrane.24. The solenoid valve ...

Genetic Test for the Identification of Carriers of Complex Vertebral Malformations in Cattle

Genetic markers for identifying bovine carriers of complex vertebral malformation (CVM) disease gene are described. The genetic markers, including the microsatellite markers BM4129, INRAA003, BMS2790, ILSTS029, INRA123, BM220, HUJ246, BMS862, BMS937, BL1048, BMS2095 and BMS1266 and the bovine SLC35A3 gene, are located on bovine chromosome BTA3. The G/T polymorphism at position 559 of the bovine SLC35A3 gene is identified as being causative and diagnostic for CVM in cattle. 1. A method for identifying a Holstein-Fresian subject as a carrier of a genetic determinant for bovine complex vertebral malformation (CVM) , the method comprisingi) providing a sample comprising genetic material from a Holstein-Friesian subject;ii) obtaining from said sample genomic DNA sequences from bos Taurus autosome 3 (BTA3) comprising a region between the polymorphic microsatellite markers INRAA003 and BMS937;iii) determining the sequence of at least a part of said region;iv) determining whether said sequence comprises a sequence polymorphism that is genetically linked to the SLC35A3 gene polymorphism having a T nucleotide at a position equivalent to position 559 of SEQ ID NO:17; andv) identifying said bovine Holstein-Friesian subject as a carrier of a genetic determinant for CVM, when a sequence polymorphism linked to the SLC35A3 gene polymorphism having a T nucleotide at a position equivalent to position 559 of SEQ ID NO: 17 is detected in step iv).2. The method according to claim 1 , wherein the genetically linked sequence polymorphism is located in the region flanked by and including the polymorphic microsatellite markers INRAA003 and ILSTS029.3. The method according to claim 1 , wherein the genetically linked sequence polymorphism is the microsatellite marker INRAA003.4. The method according to claim 1 , wherein the genetically linked sequence polymorphism is the microsatellite marker BMS2790.5. The method according to claim 1 , wherein the genetically linked sequence polymorphism is ...

PRODUCTION OF AN INSTANT COFFEE PRODUCT IN HIGH YIELD

Disclosed herein is a process for production of an instant coffee product in a high yield, comprising the steps of extracting roast and ground coffee beans with water having a temperature of 80° C. or less, to produce a first extract and spent coffee grounds, adding water to the spent coffee grounds to produce an aqueous suspension, hydrolysing the aqueous suspension using a hydrolysing enzyme to produce a second extract and spent remains, adding the first extract to the second extract, optionally after concentration and/or drying of the second extract, to obtain a combined extract, and drying the combined extract to obtain an instant coffee product. The high yield is obtained due to the reduction of enzyme inhibiting substances. 1. A process for production of an instant coffee product in a high yield , comprising:extracting roast and ground coffee beans with water having a temperature of 80° C. or less, to produce a first extract and spent coffee grounds;pre-treating the spent coffee grounds, wherein the pre-treatment comprises adding water to the spent coffee grounds, steam exploding the spent coffee grounds, and separating into an intermediate extract and pre-treated spent coffee grounds, and wherein the steam explosion is performed in the temperature range of 50-175° C., at a pressure of 0.1 to 10 bar for 0.1 to 5 hours;adding water to the pre-treated spent coffee grounds to produce an aqueous suspension;hydrolysing the aqueous suspension using a hydrolysing enzyme to produce a second extract and spent remains;adding the first extract and the intermediate extract to the second extract, optionally after concentration or drying of the intermediate or second extract, to obtain a combined extract; anddrying the combined extract to obtain an instant coffee product.2. The process according to claim 1 , wherein the extraction is performed at a temperature in the range of 10-80° C.3. The process according to claim 1 , wherein the extraction is performed in a time range ...

PRODUCTION OF A COFFEE EXTRACT PRESERVING FLAVOUR COMPONENTS

Disclosed herein is a process for preparing a coffee extract, comprising the steps of: providing a mixture of roasted coffee beans and water, milling the mixture of roast coffee beans and water in a pressurised chamber, and separating the milled mixture in a liquid coffee extract and spent coffee grounds. The coffee extract maintains many of the flavour components of the roasted beans. 1. A process for preparing a coffee extract , comprising:providing a mixture of roasted coffee beans and water,milling the mixture of roast coffee beans and water in a pressurised chamber, andseparating the milled mixture in a liquid coffee extract and spent coffee grounds.2. The process according to claim 1 , wherein the water is heated prior to the mixing with roast coffee beans to achieve a mixture of 80° C. or less.3. The process according to claim 1 , wherein the water is heated prior to the mixing with roast coffee beans to achieve a mixture of 90° C. or less.4. The process according to claim 1 , wherein the water is heated prior to the mixing with roast coffee beans to achieve a mixture of 95° C. or less.5. The process according to claim 1 , wherein the milled mixture is maintained in the pressurised chamber for 5 min to 2 hours before separation.6. The process according to claim 1 , wherein the milled mixture is maintained in the pressurised chamber for 10 min to 1 hour before separation.7. The process according to claim 1 , wherein the mixing of roast coffee and water according to the mixture occurs in a pressurised chamber.8. The process according to claim 1 , wherein a major amount of the COliberated from the roast coffee beans during one or more of the mixing or the milling of the mixture is maintained together with the mixture of roast coffee and water.9. The process according to claim 1 , wherein the pressure of the milled mixture prior to the separation is reduced.10. The process according to claim 1 , wherein the temperature is reduced to between 0 and 30° C. prior to ...

VALVE

The invention relates to a valve () comprising a main valve (), a pilot valve (), a housing (), an inlet () and an outlet (). Opening and closing of the main valve () is controlled by the pilot valve (). A pilot valve seat () is arranged in a diaphragm (). A pilot chamber () is arranged in the housing () separated from the inlet () and the outlet () by the diaphragm (). Task of the invention is to provide a valve with a lower cost. According to the invention a support member () supports the diaphragm (), wherein the support member () is guided in the housing, and wherein a radial gap () is arranged between the radially outer end of the diaphragm () and the housing () in a radial direction perpendicular to the opening direction of the pilot valve (). Thereby, a cheaper, less resistant material for the diaphragm can be used. 1. A valve comprising a main valve , a pilot valve , a housing , an inlet and an outlet , wherein opening and closing of the main valve is controlled by the pilot valve , and wherein a pilot valve seat is arranged in a diaphragm , and wherein a pilot chamber is arranged in the housing separated from the inlet and the outlet by the diaphragm , wherein , a support member supports the diaphragm , and the support member is guided in the housing , and wherein a radial gap is arranged between the radially outer end of the diaphragm and the housing in a radial direction perpendicular to the opening of the pilot valve.2. The valve according to claim 1 , wherein claim 1 , the support member is guided in a cylindrical bore of the housing.3. The valve according to claim 2 , wherein claim 2 , the support member is guided in the bore by fitting into the bore at a circumferential claim 2 , radially outer end of the support member.4. The valve according to claim 2 , wherein claim 2 , the diaphragm has a larger diameter than the bore.5. The valve according to claim 1 , wherein claim 1 , the support member comprises a radially extending bottom plate and a ...

VISUAL INDICATORS OF USER ATTENTION IN AR/VR ENVIRONMENT

A method of notifying a user about attention from another user in an augmented reality/virtual reality (AR/VR) system is provided. The method includes displaying a first image on a first electronic display to a first user of the AR/VR system and, upon detecting a gaze of the first user at a second user of the AR/VR system or the second user's avatar in the first image, notifying the second user about the gaze of the first user by displaying a second image on a second electronic display to the second user, the second image having a visual cue of the gaze of the first user. 1. A method in a wearable display of an AR/VR system , the method comprising:displaying, using the wearable display, an image to a second user of the AR/VR system, the image comprising a visual cue of a gaze of a first user of the AR/VR system directed to the second user or an avatar of the second user,wherein the gaze of the first user directed to the second user or the avatar of the second user has been detected by a processor executing instructions to process eye tracking data of the first user.2. The method of claim 1 , wherein the image comprising the visual cue is displayed when the processor executed instructions to determine that eyes of the first user have looked at the second user or the second user's avatar for at least a predefined time interval.3. The method of claim 1 , wherein the image comprising the visual cue is displayed when a gaze direction of the first user at the second user has been detected.4. The method of claim 3 , wherein the image comprising the visual cue is displayed when at least one of a gaze vergence of the first user at the second user or a pupil dilation of the first user has been detected.5. The method of claim 1 , wherein the image has been absent the visual cue before the gaze of the first user.6. The method of claim 1 , wherein the image comprising the visual cue is displayed to the second user when at least one of a gaze direction or a gaze vergence of the ...

AUDIO INDICATORS OF USER ATTENTION IN AR/VR ENVIRONMENT

A method of notifying a user about attention from another user in an augmented reality/virtual reality (AR/VR) system is provided. The method includes displaying a first image on a first electronic display to a first user of the AR/VR system and, upon detecting a gaze of the first user at a second user of the AR/VR system or the second user's avatar in the first image, notifying the second user about the gaze of the first user by changing a parameter of an audio communication channel from the first user to the second user, so as to make the first user more audible to the second user. 1. A method in a wearable display of an AR/VR system , the method comprising:sounding, using the wearable display, an audio to a second user of the AR/VR system, wherein the audio originated from a first user of the AR/VR system and has a parameter of an audio communication channel from the first user to the second user, wherein the parameter is changed from a first value to a second value, so as to make the first user more audible to the second user;wherein a gaze of the first user directed to the second user or an avatar of the second user in an image displayed to the first user has been detected by a processor executing instructions to process eye tracking data of the first user.2. The method of claim 1 , wherein the parameter is changed from the first value to the second value when the processor executed instructions to determine that eyes of the first user have looked at the second user or the second user's avatar for at least a predefined time interval.3. The method of claim 1 , wherein the parameter is changed from the first value to the second value when a gaze direction of the first user at the second user has been detected.4. The method of claim 3 , wherein the parameter is changed from the first value to the second value when at least one of a gaze vergence of the first user at the second user or a pupil dilation of the first user has been detected.5. The method of claim 1 , ...

COMPOSITION, MARKING AND KIT OF PARTS FOR FORMING A MARKING, SUCH AS A ROAD MARKING

The disclosure relates to a composition adapted to be applied to a surface () to form a marking (), wherein the composition comprises a base composition (), and coated glass beads (), wherein the coated glass beads are mixed with the base composition (), wherein the coated glass beads () are coated with a non-translucent coating material () which coating material, when the composition has been applied to a surface to form a marking, is adapted to be worn off at any exposed portion of the glass bead thereby allowing light to enter into the glass bead () at said exposed worn off portion and which coating material () is adapted to form a retro-reflective coating () reflecting light which has passed into the glass bead () to be reflected back through the glass bead () and out through said exposed portion where the coating has been worn off. The disclosure also relates to a marking formed of said composition, to a kit of parts for forming a marking on a surface and to a marking formed of such a kit of parts. 1. A composition adapted to be applied to a surface to form a marking , wherein the composition comprisesa base composition, and wherein the coated glass beads are mixed with the base composition,', 'wherein the coated glass beads are coated with a coating material which coating material, when the composition has been applied to a surface to form a marking, is adapted to be worn off at any exposed portion of the glass bead thereby allowing light to enter into the glass bead at said exposed worn off portion and which coating material is adapted to form a retro-reflective coating reflecting light which has passed into the glass bead to be reflected back through the glass bead and out through said exposed portion where the coating has been worn off,', 'wherein the coating is non-translucent, and', 'wherein the coating, when coated on premix glass beads according to EN1424 class A having a size within 180 and 600 μm and with the coated glass beads being provided in an ...

HEADSET ADJUSTMENT FOR OPTIMAL VIEWING

A wearable display system includes a headset and a display module in the headset. The display module includes an electronic display for displaying images to the user. A camera is provided in the headset. The camera is configured for obtaining an image of an eye area of the user. A processing module of the wearable display system is configured to use the camera to determine an offset of a current eye position of the user wearing the headset, relative to an optimal eye position in an eyebox of the headset. The processing module is configured to determine a direction of adjustment of the headset to lessen the offset and provide an instruction to perform the adjustment of the headset in the determined direction. 1. A method for a headset adjustment , the headset comprising a sensor and a display module comprising an electronic display for displaying images to a user , the method comprising:using the sensor to determine an offset of a current eye position of the user wearing the headset relative to an optimal eye position in an eyebox of the headset;determining a direction of adjustment of the headset to lessen the offset; andproviding an instruction to perform the adjustment of the headset in the determined direction.2. The method of claim 1 , wherein providing the instruction to perform the adjustment comprises displaying claim 1 , by the display module claim 1 , a visual cue to the user for manual adjustment of the headset by the user to lessen the offset.3. The method of claim 1 , wherein providing the instruction to perform the adjustment comprises providing a command to a motorized stage to at least one of translate or reorient at least a portion of the display module of the headset to lessen the offset.4. The method of claim 3 , wherein the command is at least one of to translate or to rotate the display module in the headset.5. The method of claim 3 , wherein the command is at least one of to translate or to rotate an imaging component of the display module.6. ...

POLYMORPHIC FORMS AND PROCESS

A process for preparing an amorphous form of a compound of formula (I) 2. The process of wherein the 3 claim 1 ,3′-Dideoxy-3 claim 1 ,3′-bis-[4-(3-fluorophenyl)-1H-1 claim 1 ,2 claim 1 ,3-triazol-1-yl]-1 claim 1 ,1′-sulfanediyl-di-β-D-galactopyranoside used as starting material may be any crystalline form.3. The process of claim 2 , wherein any one of polymorphic forms 1 to 6 of the compound of formula (I) or mixtures thereof is used as the starting material.4. The process of claim 1 , wherein the organic solvent is acetone.5. The process of claim 1 , wherein the mixture of organic solvent and water is a mixture of acetone and water.6. The process of claim 1 , wherein the mixture of organic solvent and water is a mixture of acetone and water having a ratio of acetone:water claim 1 , on a volume basis claim 1 , in a range of 50:50 to 80:20.7. The process of claim 1 , wherein the dissolved compound is introduced in a drying chamber at a feed concentration of from 0.5% to 20% by weight.8. The process of claim 7 , wherein the drying chamber has a drying gas temperature at an inlet of from 120-160° C.9. The process of claim 8 , wherein the drying chamber has a drying gas temperature at an outlet of from 60-90° C.10. The process of claim 9 , wherein a drying time in the drying chamber is from 30-120 minutes.11. A dry powder composition comprising amorphous compound of formula (I) in an amount of 0.15 to 50 mg having a Fine Particle Fraction (FPF) above 60% and mean mass aerodynamic diameter (MMAD) values in a respirable range.12. The dry powder composition of claim 11 , wherein the amorphous compound of formula (I) is made by spray-drying a solution of 3 claim 11 ,3′-Dideoxy-3 claim 11 ,3′-bis-[4-(3-fluorophenyl)-1H-1 claim 11 ,2 claim 11 ,3-triazol-1-yl]-1 claim 11 ,1′-sulfanediyl-di-β-D-galactopyranoside in an organic solvent or a mixture of organic solvent and water. This application is a continuation of U.S. patent application Ser. No. 16/062,206, filed Jun. 14, 2018, ...

NOVEL GALACTOSIDE INHIBITORS OF GALECTINS

The present invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore, the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. 114-. (canceled)16. The compound of claim 15 , wherein Ris H or F.17. The compound of claim 15 , wherein Ris H or F.18. The compound of claim 15 , wherein Ris H or F.19. The compound of claim 15 , wherein Ris H or F.20. The compound of claim 15 , wherein Ris H or F.21. The compound of claim 15 , wherein Ris a branched Calkyl.22. The compound of claim 15 , wherein Ris a 6-membered heterocyclic group being saturated and having 1-2 hetero atoms and 3-5 carbon atoms claim 15 , optionally substituted with a Calkyl.23. The compound of claim 15 , wherein Ris selected from the group consisting of: a piperidinyl claim 15 , piperazinyl claim 15 , morpholinyl claim 15 , and tetrahydropyranyl claim 15 , optionally substituted with a Calkyl.24. The compound of claim 15 , wherein Ris H.25. The compound of claim 15 , wherein the compound is selected from the group consisting of:3,3′-Dideoxy-3-[4-(morpholin-4-yl)-1H-1,2,3-triazol-1-yl]-3′-[4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl]-1,1′-sulfanediyl-di-β-D-galactopyranoside,3,3′-Dideoxy-3-[4-(4-methylpiperazin-1-yl)-1H-1,2,3-triazol-1-yl]-3′-[4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl]-1,1′-sulfanediyl-di-β-D-galactopyranoside,3,3′-Dideoxy-3-[4-(piperidin-4-yl)-1H-1,2,3-triazol-1-yl]-3′-[4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl]-1,1′-sulfanediyl-di-β-D-galactopyranoside,3,3′-Dideoxy-3-[4-(tetrahydropyran-4-yl)-1H-1,2,3-triazol-1-yl]-3′-[4(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl]-1,1′-sulfanediyl-di-β-D-galactopyranoside, and3,3′-Dideoxy-3-[4-(propan-2-yl)-1H-1,2,3-triazol-1-yl]-3′-[4-(3,4, ...

POLYMORPHIC FORMS AND PROCESS

The present invention relates to a polymorph of a compound of formula (I) 115-. (canceled)18. The polymorph of wherein the compound of formula (I) is 3 claim 16 ,3′-Dideoxy-3 claim 16 ,3′-bis-[4-(3-fluorophenyl)-1H-1 claim 16 ,2 claim 16 ,3-triazol-1-yl]-1 claim 16 ,1′-sulfanediyl-di-β-D-galactopyranoside and has the polymorphic form 1 as identified in the XRPD diffractogram in .19. The polymorph of wherein the compound of formula (I) is 3 claim 16 ,3′-Dideoxy-3 claim 16 ,3′-bis-[4-(3-fluorophenyl)-1H-1 claim 16 ,2 claim 16 ,3-triazol-1-yl]-1 claim 16 ,1′-sulfanediyl-di-β-D-galactopyranoside as a hydrate.20. The polymorph of wherein the 3 claim 19 ,3′-Dideoxy-3 claim 19 ,3′-bis-[4-(3-fluorophenyl)-1H-1 claim 19 ,2 claim 19 ,3-triazol-1-yl]-1 claim 19 ,1′-sulfanediyl-di-β-D-galactopyranoside hydrate contains 3-5% water (weight %).21. The polymorph of wherein the polymorph is micronized.22. The polymorph of wherein the polymorph is micronized to a size that can reach the bronchioles and/or the alveoli of the human.23. A pharmaceutical composition comprising the polymorph of claim 16 , and optionally a pharmaceutically acceptable additive.24. A process of making a polymorph Form 1 of comprising the steps of suspending or dissolving 3 claim 16 ,3′-Dideoxy-3 claim 16 ,3′-bis-[4-(3-fluorophenyl)-1H-1 claim 16 ,2 claim 16 ,3-triazol-1-yl]-1 claim 16 ,1′-sulfanediyl-di-β-D-galactopyranoside in an organic solvent and then making Form 1 by temperature cycling claim 16 , crash cooling claim 16 , evaporation claim 16 , or a combination thereof.25. A method for treatment of pulmonary fibrosis in a human comprising administering to the lung tissue of the human an amount of the polymorph of effective to treat said pulmonary fibrosis.26. The method of wherein the administration is carried out by a dry powder inhaler.27. The method of wherein the administration is carried out by a monodose dry powder inhaler.28. The method of wherein the polymorph is administered to the bronchioles ...

Catalyst for Use in the Selective Catalytic Reduction (SCR) of Nitrogen Oxides

The present invention pertains to a catalyst for use in the selective catalytic reduction (SCR) of nitrogen oxides comprising a monolithic substrate and a coating A, which comprises an oxidic metal carrier comprising an oxide of titanium and a catalytic metal oxide which comprises an oxide of vanadium wherein the mass ratio vanadium/titanium is 0.07 to 0.26. 1. A catalyst for use in the selective catalytic reduction (SCR) of nitrogen oxides comprisinga monolithic substrate anda coating A which comprises an oxidic metal carrier comprising an oxide of titanium and a catalytic metal oxide which comprises an oxide of vanadium wherein the mass ratio vanadium/titanium is 0.07 to 0.22.2. The catalyst according to claim 1 , wherein the mass ratio vanadium/titanium is 0.1 to 0.21.3. The catalyst according to claim 1 , wherein the monolithic substrate comprises wherein the monolithic substratea) comprises corrugated sheets of glass fiber,b) comprises corrugated ceramic paper stacked up or rolled up,c) comprises a corrugated sheets with a flat liner, ord) is an extrudate comprising vanadium pentoxide and titanium dioxide.4. The catalyst according to claim 1 , wherein the catalytic metal oxide of coating A which comprises an oxide of vanadium comprises vanadium pentoxide (VO).5. The catalyst according to claim 4 , wherein the catalytic metal oxide of coating A which comprises an oxide of vanadium comprises in addition an oxide of tungsten and/or molybdenum.6. The catalyst according to claim 1 , wherein the oxidic metal carrier of coating A which comprises an oxide of titanium comprises titanium dioxide.7. The catalyst according to claim 6 , wherein the oxidic metal carrier of coating A which comprises an oxide of titanium comprises in addition an oxide of aluminum claim 6 , cerium claim 6 , zirconium or mixtures claim 6 , mixed oxides or compounds comprising at least one of these oxides.8. The catalyst according to claim 1 , wherein the oxidic metal carrier consists of either ...

Use of i) a polyglycol and n) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse

Abuse resistant polyglycol-based pharmaceutical compositions are disclosed. The composition contains one or more polyglycols and one or more active substances and it is resistant to crushing, melting and/or extraction. Moreover, such compositions have the same or lower solubility in ethanolic-aqueous medium, i.e. they are not subject to ethanol-induced dose dumping effect.

Controlled release pharmaceutical compositions for prolonged effect

Layered pharmaceutical composition suitable for oral use in the treatment of diseases where absorption takes place over a large part of the gastrointestinal tract. The composition comprising A) a solid inner layer comprising i) an active substance, and ii) one or more disintegrants/exploding agents, one of more effervescent agents or a mixture thereof. the solid inner layer being sandwiched between two outer layers B1) and B2), each outer layer comprising iii) a substantially water soluble and/or crystalline polymer or a mixture of substantially water soluble and/or crystalline polymers, the polymer being a polyglycol in the form of one of a) a homopolymer having a MW of at least about 100,000 daltons, and b) a copolymer having a MW of at least about 2,000 daltons, or a mixture thereof, and iv) an active substance, which is the same as in said solid inner layer A), and layer A being different from layer B, the layered composition being coated with a coating C) that has at least one opening exposing at least one surface of said outer layer, the coating being substantially insoluble in and impermeable to fluids and comprising a polymer, and the composition having a cylindrical form optionally with one or more tapered ends, wherein the ratio between the surface area of one end surface of the cylinder and the length of the cylinder is in a range of from 0.02 to 45 mm.

Laccase mutants

The present invention relates to a method of designing laccase mutants with improved stability properties, which method is based on the hitherto unknown three-dimensional structure of Coprinus cinereus laccase.

Laccase mutants

The present invention relates to a method of designing laccase mutants with improved stability properties, which method is based on the hitherto unknown three-dimensional structure of Coprinus cinereus laccase.

Laccase mutants

The present invention relates to a method of designing laccase mutants with improved stability properties, which method is based on the hitherto unknown three-dimensional structure of Coprinus cinereus laccase.

Laccase mutants

The present invention relates to a method of designing laccase mutants with improved stability properties, which method is based on the hitherto unknown three-dimensional structure of Coprinus cinereus laccase.

Factor VII or VIIa-like molecules

Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.

Interferon-β variants and conjugates

The present invention provides new interferon β conjugates, methods of preparing such conjugates and the use of such conjugates in therapy, in particular for the treatment of multiple sclerosis.

Factor VII or VIIA-like conjugates

The present invention relates to novel factor VII (FVII) or Factor VIIa (FVIIa) polypeptide conjugates, to their preparation and use in therapy, in particular for the treatment of a variety of coagulation-related disorders. These novel polypeptide conjugates comprise at least one non-polypeptide moiety covalently attached to a polypeptide, wherein the amino acid sequence of the polypeptide differs from that of wild-type FVII or FVIIa in that at least one amino acid residue comprising an attachment group for said non-polypeptide moiety has been introduced or removed. The conjugates of the present invention have one or more improved properties as compared to commercially available rFVIIa, including increased functional in vivo half-life and/or increased plasma half-life, and/or increased bioavailability and/or reduced sensitivity to proteolytic degradation.

New interferon beta-like molecules

The invention relates to a conjugate exhibiting interferon β activity and comprising at least one first non-polypeptide moiety covalently attached to an interferon β polypeptide, the amino acid sequence of which differs from that of wildtype human interferon β in at least one introduced and at least one removed amino acid residue comprising an attachment group for said first non-polypeptide moiety. The first non-polypeptide moiety is e.g. a polymer molecule or a sugar moiety. The conjugate finds particular use in therapy. The invention also relates to a glycosylated variant of a parent interferon β (IFNB) polypeptide comprising at least one in vivo glycosylation site, wherein an amino acid residue of said parent polypeptide located close to said glycosylation site has been modified to obtain the variant polypeptide having an increased glycosylation as compared to the glycosylation of the parent polypeptide.

Interferon-beta conjugates

A conjugate exhibiting interferon β activity and comprising at least one first non-polypeptide moiety covalently attached to an interferon β polypeptide, the amino acid sequence of which differs from that of wildtype human interferon β in at least one introduced and at least one removed amino acid residue comprising an attachment group for said first non-polypeptide moiety. The first non-polypeptide moiety is e.g. a polymer molecule or a sugar moiety. The conjugate finds particular use in therapy.

L-amino acid oxidase

The present invention relates to a novel L-amino acid oxidase having a broad substrate specificity and being obtainable from the species Trichoderma harzianum. The enzyme of the invention may advantageously be incorporated into detergent compositions designed to inhibit the transfer of dye from a dyed fabric to another fabric during washing.

Myxococcaceae peroxidase

The present invention relates to a novel peroxidase preparation characterized by being producible by cultivation of a peroxidase producing strain of the family Myxococcaceae.

Bleaching process comprising use of a phenol oxidizing enzyme, a hydrogen peroxide source and an enhancing agent

The present invention relates to a process for providing a bleached look in the colour density of the surface of dyed fabric, especially cellulosic fabric such as denim, comprising use of a phenol oxidizing enzyme such as a peroxidase or a laccase, a hydrogen peroxide source and an enhancing agent represented by formula (I).

H2 O2 -stable peroxidase variants

The present invention relates to a novel variant of peroxidase with improved stability at alkaline conditions, and a bleaching or detergent composition comprising the peroxidase variant.

Myxococcus peroxidase

A purified peroxidase obtained from a strain of Myxococcus, having a molecular weight of about 40 kDA as determined by SDS-PAGE, which is stable up to 60° C. for 2 hours without loss of activity, and retains activity at pH 10.5.

Bleaching process comprising use of phenol oxidizing enzyme, a hydrogen peroxide source and an enhancing agent

The present invention relates to a process for providing a bleached look in the color density of the surface of dyed fabric, especially cellulosic fabric such as denim, comprising use of a phenol oxidizing enzyme such as a peroxidase or a laccase, a hydrogen peroxide source and an enhancing agent represented by formula (I). ##STR1##

EXPANSION VALVE

An expansion valve () is described to include a housing () having in inlet port () and an outlet port (), a valve seat () arranged between the inlet port () and the outlet port (), a valve element () movable over an operating stroke between a closed position at the valve seat () and an opened position away from the valve seat (), and an actuator (), wherein the actuator () has an electric rotary motor () acting on the valve element () by means of a threaded spindle () and a nut (), wherein one of spindle () and nut () is rotatably driven by the motor () and the other one is rotatably fixed. Such an expansion valve should have the possibility for a simple assembly. To this end, in a disassembled condition of housing () and actuator (), the actuator () has a mounting stroke which is at least two times the operating stroke, wherein the mounting stoke extends the operating stroke.

Purification of factor VII

Adiponectin fragments and conjugates

The invention relates to a conjugate comprising an adiponectin polypeptide, and a first non-polypeptide moiety covalently attached to the adiponectin polypeptide, wherein the adiponectin polypeptide comprises an amino acid residue having an attachment group for said first non-polypeptide moiety, wherein said amino acid residue has been introduced in a position that in the parent adiponectin is occupied by a surface exposed amino acid residue. The non-polypeptide moiety may be a polymer, e.g. PEG. Further described is an isolated complex comprising an adiponectin trimer and calcium ions. The conjugate or complex is used in the treatment of disorders such as type 2 diabetes, cardiovascular disease and septic shock.

Squeeze for rice firewood.

Adiponectin fragments and conjugates

The invention relates to a conjugate comprising an adiponectin polypeptide, and a first non-polypeptide moiety covalently attached to the adiponectin polypeptide, wherein the adiponectin polypeptide comprises an amino acid residue having an attachment group for said first non-polypeptide moiety, wherein said amino acid residue has been introduced in a position that in the parent adiponectin is occupied by a surface exposed amino acid residue.

Peroxidase variant with improved stability for hydrogen peroxide in alkaline conditions bleaching composition and detergent composition

Polymorphic forms and process

The present invention relates to a polymorph of a compound of formula (I) This polymorph is particularly suitable in treating IPF by pulmonary administration.

A method for preparing modified polypeptides

Methods for producing polypeptide with altered immunogenicity or improved stability properties are disclosed. The methods involve a) expressing a diversified population of nucleotide sequences encoding a polypeptide of interest, b) screening the polypeptides expressed in step a) for function, immunogenicity and/or stability, c) selecting functional polypeptides having altered immunogenicity and/or increased stability, e.g. functional in vivo half-life as compared to the polypeptide of interest, and d) optionally subjecting the nucleotide sequence encoding the polypeptide selected in step c) to one or more repeated cycles of steps a)-c). In a further step the expressed polypeptides of step a) or c) can be conjugated to at least one non-polypeptide moiety.

FACTOR VII OR VIIa POLYPEPTIDE VARIANTS

The present invention relates to novel polypeptide variants of factor VII (FVII) or factor VIIa (FVIIa) polypeptides, where said variants comprise an amino acid substitution in position 10 and 32 and where said variants further comprise a sugar moiety covalently attached to an introduced in vivo N-glycosylation site located outside of the Gla domain. Such polypeptide variants are useful in therapy, in particular for the treatment of a variety of coagulation-related disorders, such as trauma.

Antimicrobial activity of laccases

A conjugate exhibiting interferon beta, a nucleotide sequence, an expressing vector, a host cell containing such a nucleotide sequence, method for the preparation thereof, pharmaceutical composition containing the same and its use

A conjugate exhibiting interferon beta activity and comprising at least one first non-polypeptide moiety covalently attached to an interferon beta polypeptide, the amino acid sequence of which differs from that of wildtype human interferon beta in at least one introduced and at least one removed amino acid residue comprising an attachment group for said first non-polypeptide moiety. The first non-polypeptide moiety is e.g. a polymer molecule or a sugar moiety. The conjugate finds particular use in therapy.

Adiponectin fragments and conjugates

The invention relates to a conjugate comprising an adiponectin polypeptide, and a first non-polypeptide moiety covalently attached to the adiponectin polypeptide, wherein the adiponectin polypeptide comprises an amino acid residue having an attachment group for said first non-polypeptide moiety, wherein said amino acid residue has been introduced in a position that in th e parent adiponectin is occupied by a surface exposed amino acid residue. The non-polypeptide moiety may be a polymer, e.g. PEG. Further described is an isolated complex comprising an adiponectin trimer and calcium ions. The conjugate or complex is used in the treatment of disorders such as type 2 diabetes, cardiovascular disease and septic shock.

FACTOR VII OR VIIa−LIKE MOLECULES

The present invention relates to novel factor VII (FVII) or Factor VIIa (FVIIa) polypeptide conjugates, to their preparation and use in therapy, in particular for the treatment of a variety of coagulation-related disorders. These novel polypeptide conjugates comprise at least one non-polypeptide moiety covalently attached to a polypeptide, wherein the amino acid sequence of the polypeptide differs from that of wild-type FVII or FVIIa in that at least one amino acid residue comprising an attachment group for said non-polypeptide moiety has been introduced or removed. The conjugates of the present invention have one or more improved properties as compared to commercially available rFVIIa, including increased functional in vivo half-life and/or increased plasma half-life, and/or increased bioavailability and/or reduced sensitivity to proteolytic degradation.

Purification of factor vii

Activation and degradation of FVII during purification by means of a number of chromatographic purification steps is controlled by the presence of Zn++ at least in one of the purification steps.

Production of a coffee extract that preserves flavor components

"PRODUÇÃO DE UM EXTRATO DE CAFÉ QUE PRESERVA COMPONENTES DE SABOR". É divulgado aqui um processo para preparar um extrato de café, compreendendo as etapas de: prover uma mistura de grãos de café torrados e água, moer a mistura de grãos de café torrados e água em uma câmara pressurizada, e separar a mistura moída em um extrato de café líquido e pó de café gasto. O extrato de café mantém muitos dos componentes de sabor dos grãos torrados. "PRODUCTION OF A COFFEE EXTRACT THAT PRESERVES FLAVOR COMPONENTS". Disclosed herein is a process for preparing a coffee extract, comprising the steps of: providing a mixture of roasted coffee beans and water, grinding the mixture of roasted coffee beans and water in a pressurized chamber, and separating the ground mixture in a liquid coffee extract and spent coffee grounds. Coffee extract retains many of the flavor components of roasted beans.

Controlled release pharmaceutical compositions for prolonged effect

Layered pharmaceutical composition suitable for oral use in the treatment of diseases where absorption takes place over a large part of the gastrointestinal tract. The composition comprising A) a solid inner layer comprising i) an active substance, and ii) one or more disintegrants/exploding agents, one of more effervescent agents or a mixture thereof. the solid inner layer being sandwiched between two outer layers B1) and B2), each outer layer comprising iii) a substantially water soluble and/or crystalline polymer or a mixture of substantially water soluble and/or crystalline polymers, the polymer being a polyglycol in the form of one of a) a homopolymer having a MW of at least about 100,000 daltons, and b) a copolymer having a MW of at least about 2,000 daltons, or a mixture thereof, and iv) an active substance, which is the same as in said solid inner layer A), and layer A being different from layer B, the layered composition being coated with a coating C) that has at least one opening exposing at least one surface of said outer layer, the coating being substantially insoluble in and impermeable to fluids and comprising a polymer, and the composition having a cylindrical form optionally with one or more tapered ends, wherein the ratio between the surface area of one end surface of the cylinder and the length of the cylinder is in a range of from 0.02 to 45 mm.

Factor VII or VIIa - Like Molecules

Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.

Interferon Beta-Like Molecules

The invention relates to a conjugate exhibiting interferon β (IFNB) activity and comprising at least one first non-polypeptide moiety covalently attached to an IFNB polypeptide, the amino acid sequence of which differs from that of wildtype human IFNB in at least one introduced and at least one removed amino acid residue comprising an attachment group for said first non-polypeptide moiety. The first non-polypeptide moiety is e.g. a polymer molecule or a sugar moiety. The conjugate finds particular use in therapy. The invention also relates to a glycosylated variant of a parent IFNB polypeptide comprising at least one in vivo glycosylation site, wherein an amino acid residue of said parent polypeptide located close to said glycosylation site has been modified to obtain the variant polypeptide having an increased glycosylation as compared to the glycosylation of the parent polypeptide.

Controlled release pharmaceutical compositions for prolonged effect

Layered pharmaceutical composition suitable for oral use in the treatment of diseases where absorption takes place over a large part of the gastrointestinal tract. The composition comprising A) a solid inner layer comprising i) an active substance, and ii) one or more disintegrants/exploding agents, one of more effervescent agents or a mixture thereof. the solid inner layer being sandwiched between two outer layers B1) and B2), each outer layer comprising iii) a substantially water soluble and/or crystalline polymer or a mixture of substantially water soluble and/or crystalline polymers, the polymer being a polyglycol in the form of one of a) a homopolymer having a MW of at least about 100,000 daltons, and b) a copolymer having a MW of at least about 2,000 daltons, or a mixture thereof, and iv) an active substance, which is the same as in said solid inner layer A), and layer A being different from layer B, the layered composition being coated with a coating C) that has at least one opening exposing at least one surface of said outer layer, the coating being substantially insoluble in and impermeable to fluids and comprising a polymer, and the composition having a cylindrical form optionally with one or more tapered ends, wherein the ratio between the surface area of one end surface of the cylinder and the length of the cylinder is in a range of from 0.02 to 45 mm.

Protein c or activated protein c-like molecules

The present invention relates to novel conjugates between polypeptide variants of pro-tein C and a non-polypeptide moiety, such as PEG or sugar moieties. In particular, the present invention provides novel protein C conjugates having an increased resistance to inactivation by e.g. human plasma and a1-antitrypsin. Consequently, such conjugates have an increased in vivo half-life. Preferred examples include protein C conjugates, wherein at least one additional in vivo N-glycosylation site has been introduced. The conjugates of the invention are useful for treating a variety of diseases, including septic shock.

Furniture and method of assembling furniture

A piece of furniture, for example a chair (2), with integrated shell (4) forming a furniture part, e.g. a seat (6) and a backrest (8), and a number of legs (10), e.g. four legs that are fastened at the underside of the furniture part or the seat (6), where the shell (4) is made by injection moulding of fibre reinforced plastic, and where the furniture part or seat (6) is provided with sockets (22) at the underside for receiving and retaining end parts (16) of the legs (10) which have identical shape. The legs (10) are made of steel with elongated, straight parts (12) and end parts (16) angularly bent in relation thereto and designed with an elongated conical guide pin (18) with external grooves. The sockets (22) at the underside of the furniture part or seat (6) are designed with an internal shape which is complementary to the external grooves (18) of the end parts (16) of the legs (10). Moreover, there is disclosed a method for establishing a joint, e.g. a furniture joint. In a very simple way is hereby provided a furniture or a chair adapted for packing and shipping in separated condition, and which subsequently is readily assembled by the consumer in a simple and unambiguously correct way.

Rectal insulin for treatment of inflammatory bowel diseases

The present disclosure relates to compositions comprising insulin and to be administered rectally for treatment of inflammatory bowel diseases and inflammation-induced colorectal tumour and/or cancer.

Bleaching process comprising use of a phenol oxidizing enzyme, a hydrogen peroxide source and an enhancing agent

The present invention relates to a process for providing a bleached look in the colour density of the surface of dyed fabric, especially cellulosic fabric such as denim, comprising use of a phenol oxidizing enzyme such as a peroxidase or a laccase, a hydrogen peroxide source and an enhancing agent represented by formula (I).

New interferon beta-like molecules

A találmány tárgya b-interferon-aktivitást mutató konjugátum, amely b-interferon-polipeptidből és ahhoz kovalensen kapcsolt, első nempolipeptid természetű fragmentumból áll. A vad típusú, emberi b-interferon aminosav-szekvenciájától legalább egy aminosavbeillesztése, illetve legalább egy aminosav eltávolítása tekintetébeneltérő b-interferon aminosav-szekvenciája kötőcsoportot tartalmaz anem polipeptid természetű fragmentum megkötésére. Az első, nempolipeptid természetű fragmentum lehet például polimermolekula, vagycukorcsoport. A konjugátum előnyösen alkalmazható terápiás célokra. Ó FIELD OF THE INVENTION The present invention relates to a conjugate having interferon-b activity consisting of a b-interferon polypeptide and a covalently linked non-polypeptide fragment thereof. The amino acid sequence of at least one amino acid sequence of at least one amino acid from the wild type human interferon b-interferon, or the removal of at least one amino acid, contains a binding group for binding an anem polypeptide-like fragment. The first non-polypeptide-like fragment may be, for example, a polymer molecule, or a sugar group. The conjugate is preferably used for therapeutic purposes. HE

Closure for pigfolds.

Production of an instant coffee product in high yield

Disclosed herein is a process for production of an instant coffee product in a high yield, comprising the steps of extracting roast and ground coffee beans with water having a temperature of 80°C or less, to produce a first extract and spent coffee grounds, adding water to the spent coffee grounds to produce an aqueous suspension, hydrolysing the aqueous suspension using a hydrolysing enzyme to produce a second extract and spent remains, adding the first extract to the second extract, optionally after concentration and/or drying of the second extract, to obtain a combined extract, and drying the combined extract to obtain an instant coffee product. The high yield is obtained due to the reduction of enzyme inhibiting substances.

Printed wiring board with enhanced structural integrity

A structural printed wiring board panel includes a multilayer printed wiring board having opposing, outer faces and interlayer interconnects that route RF, power and control signals. Connection areas are formed in or on at least on one face for connecting the interlayer interconnects and any electrical components. A metallic face sheet is secured onto at least one outer face, adding structural rigidity to the multilayer printed wiring board. A metallic face sheet can have apertures positioned to allow access to connection areas. RF components can be carried by a face sheet and operatively connected to connection areas. Antenna elements can be positioned on the same or an opposing face sheet and operatively connected to RF components to form a phased array printed wiring board (PWB) panel.

Bleaching process comprising use of a phenol oxidizing enzyme, a hydrogen peroxide source and an enhancing agent.

La presente invencion se refiere a un proceso para la prevision de una apariencia blanqueada en la densidad del color de la superficie de tela teñida, especialmente tela celulosica tal como mezclilla, que comprende el uso de una enzima oxidante de fenol tal como una peroxidasa o una lacasa, una fuente de peroxido de hidrogeno y un agente mejorador de fenotiazina o fenoxazina, representado por la formula (I).

Interferon-beta variants and conjugates

The present invention provides new interferon β conjugates, methods of preparing such conjugates and the use of such conjugates in therapy, in particular for the treatment of multiple sclerosis.

Purification of factor vii

Factor VII or VIIa-like molecules

The present application relates to factor VII (FVII) or Factor VIIa (FVIIa) polypeptide conjugates, to their preparation and use in therapy, in particular for the treatment of a variety of coagulation-related disorders. These polypeptide conjugates comprise at least one non-polypeptide moiety covalently attached to a polypeptide, wherein the amino acid sequence of the polypeptide differs from that of wild-type FVII or FVIIa in that at least one amino acid residue comprising an attachment group for said non-polypeptide moiety has been introduced or removed. The conjugates of the present application have one or more improved properties as compared to commercially available rFVIIa, including increased functional in vivo half-life and/or increased plasma half-life, and/or increased bioavailability and/or reduced sensitivity to proteolytic degradation.

Sertindole for the preventive treatment of suicidal behaviour

The present invention relates to the use of sertindole in the preparation of a pharmaceutical composition for the preventive treatment of suicidal behaviour in human subjects suffering from a psychotic illness such as schizophrenia or schizoaffective psychosis.

A conveyor and a method for operating a conveyor

Rectal insulin for treatment of inflammatory bowel diseases

Valve arrangement and diaphragm assembly for a valve arrangement

The present invention relates to a valve arrangement (1) comprising a valve housing (2), a valve inlet (3), a valve outlet (4) and a diaphragm assembly for controlling a fluid flow through the valve housing (2) from the valve inlet (3) to the valve outlet (4), the diaphragm assembly comprising a diaphragm (5) and a diaphragm plate (6) at least partially covering the diaphragm (5), the diaphragm (5) comprising one or more equalization holes (13) passing through the diaphragm (5) and the diaphragm plate (6) comprising one or more equalization openings (12) passing through the diaphragm plate (6), the equalization holes (13) being aligned with the equalization openings (12). According to the invention, the diaphragm assembly comprises an engagement zone engaging the diaphragm (5) in order to rotationally fix the diaphragm (5) and the diaphragm plate (6) with respect to each other. This has the effect that the equalization holes (13) will keep aligned with the equalization openings (12). Thus, proper function of the valve arrangement (1) is ensured at all times. Furthermore, the invention relates to a diaphragm assembly for a valve arrangement (1) as described above.

Antimicrobial activity of laccases

A method for antimicrobial treatment of microorganisms and/or viruses comprising treating with an effective amount of a fungal Laccase and one or more enhancers in the presence of oxygen, O2, the enhancers being of formula (I).

Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse

Disclosed is the use of i) one or more polyglycols selected from polyethylene glycols and/or polyethylene oxides and ii) one or more drug substances for the preparation of a pharmaceutical composition that is without ethanol induced dose dumping and wherein the drug substance is released by erosion of a matrix composition comprising said one or more polyethylene glycols and/or polyethylene oxides and said one or more drug substances, and wherein said matrix composition is partly coated with a polymer that is substantially insoluble, non-erodable and non-permeable to water leaving non-coated areas of the matrix exposed for release of the drug substance, wherein said polymer is selected from the group consisting of: ethylcellulose, cellulose acetate, cellulose propionate, cellulose nitrate, methylcellulose, carboxymethylcellulose and salts thereof, cellulose acetate phthalate, microcrystalline cellulose, ethylhydroxyethylcellulose, ethylmethylcellulose, hydroxyethylcellulose, hydroxyethylmethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxymethylcellulose and hydroxymethylpropylcellulose, poly(methyl)acrylates, polyamide, polyethylene, polyethylene terephthalate, polypropylenem polyurethane, polyvinyl acetate, polyvinyl chloride, silicone rubber, latex, polyhydroxybutyrate, polyhydroxyvalerate, teflon, polylactic acid or polyglycolic acid and copolymers thereof, the copolymers selected from the group consisting of ethylene vinyl acetate (EVA), styrene-butadienestyrene (SBS) and styrene-isoprene-styrene (SIS),copolymers of polylactic acid and polyglycolic acid and the co-polymer of methacrylategalactomannan.

Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse

Abuse resistant polyglycol-based pharmaceutical compositions are disclosed. The composition contains one or more polyglycols and one or more active substances and it is resistant to crushing, melting and/or extraction. Moreover, such compositions have the same or lower solubility in ethanolic-aqueous medium, i.e. they are not subject to ethanol-induced dose dumping effect.

Rectal insulin for treatment of inflammatory bowel diseases

The present disclosure relates to compositions comprising insulin and to be administered rectally for treatment of inflammatory bowel diseases and inflammation-induced colorectal tumour and/or cancer.

Factor vii or viia-like molecules

The present invention relates to novel factor VII (FVII) or Factor VIIa (FVIIa) polypeptide conjugates, to their preparation and use in therapy, in particular for the treatment of a variety of coagulation-related disorders. These novel polypeptide conjugates comprise at least one non-polypeptide moiety covalently attached to a polypeptide, wherein the amino acid sequence of the polypeptide differs from that of wild-type FVII or FVIIa in that at least one amino acid residue comprising an attachment group for said non- polypeptide moiety has been introduced or removed. The conjugates of the present invention have one or more improved properties as compared to commercially available rFVIIa, including increased functional in vivo half- life and/or increased plasma half-life, and/or increased bioavailability and/or reduced sensitivity to proteolytic degradation.

Continuous feed apparatus for staining specimens carried on slides

Electronic device with edge surface antenna elements and related methods

An electronic device may include a multilayer circuit board having opposing major surfaces and edge surfaces extending between the opposing major surfaces, wireless processing circuitry on at least one of the opposing major surfaces, and an antenna element on at least one of the edge surfaces. The multilayer circuit board may include a conductive trace coupling the antenna element to the wireless processing circuitry.

Composition, marking and kit of parts for forming a marking, such as a road marking

Antimicrobial activity of laccases

A method for antimicrobial treatment of microorganisms and/or viruses comprising treating with an effective amount of a fungal Laccase and one or more enhancers in the presence of oxygen, O2, the enhancers being of formula (I).

A conveyor and a method for operating a conveyor

A conveyor for slidingly conveying and decelerating or accelerating items has a conveyor track having at least one track section (5) which comprises mutually transversely spaced first and second track section parts (6, 7) defining supporting surface parts (16, 17) having different frictional surface characteristics. Flexible sheet material (8) arranged between adjacent track section parts is provided so as to prevent items and foreign matter from becoming clamped or squeezed between adjacent track section parts. Displacement means for moving the first and second track section parts in relation to each other between item supporting and item non-supporting positions are provided, whereby the rate of movement of the items along the conveyor track may be controlled. A method for operating such a conveyor is disclosed.

Novel molecules resembling beta interferon

A conjugate exhibiting interferon beta activity and comprising at least one first non-polypeptide moiety covalently attached to an interferon beta polypeptide, the amino acid sequence of which differs from that of wildtype human interferon beta in at least one introduced and at least one removed amino acid residue comprising an attachment group for said first non-polypeptide moiety. The first non-polypeptide moiety is e.g. a polymer molecule or a sugar moiety. The conjugate finds particular use in therapy.

Production of an instant coffee product in high yield

Disclosed herein is a process for production of an instant coffee product in a high yield, comprising the steps of extracting roast and ground coffee beans with water having a temperature of 80?C or less, to produce a first extract and spent coffee grounds, adding water to the spent coffee grounds to produce an aqueous suspension, hydrolysing the aqueous suspension using a hydrolysing enzyme to produce a second extract and spent remains, adding the first extract to the second extract, optionally after concentration and/or drying of the second extract, to obtain a combined extract, and drying the combined extract to obtain an instant coffee product. The high yield is obtained due to the reduction of enzyme inhibiting substances.

Amorphous form of 5-bromopyridin-3-yl 3-deoxy-3-[4-(3,4,5-trifluorophenyl)-1h-1,2,3-triazol-1-yl]-1-thio-alpha-d-galactopyranoside

The present invention relates to a stabilized amorphous form of a compound of formula (I) as well as compositions for oral administration comprising the compound of formula (I) in a therapeutically effective amount.

Headset adjustment for optimal viewing

A wearable display system includes a headset and a display module in the headset. The display module includes an electronic display for displaying images to the user. A camera is provided in the headset. The camera is configured for obtaining an image of an eye area of the user. A processing module of the wearable display system is configured to use the camera to determine an offset of a current eye position of the user wearing the headset, relative to an optimal eye position in an eyebox of the headset. The processing module is configured to determine a direction of adjustment of the headset to lessen the offset and provide an instruction to perform the adjustment of the headset in the determined direction.

Electronic device with edge surface antenna elements and related methods

An electronic device may include a multilayer circuit board having opposing major surfaces and edge surfaces extending between the opposing major surfaces, wireless processing circuitry on at least one of the opposing major surfaces, and an antenna element on at least one of the edge surfaces. The multilayer circuit board may include a conductive trace coupling the antenna element to the wireless processing circuitry.

Method for preparing modified polypeptides

Methods for producing polypeptide with altered immunogenicity or improved stability properties are disclosed. The methods involve a) expressing a diversified population of nucleotide sequences encoding a polypeptide of interest, b) screening the polypeptides expressed in step a) for function, immunogenicity and/or stability, c) selecting functional polypeptides having altered immunogenicity and/or increased stability, e.g. functional in vivo half-life as compared to the polypeptide of interest, and d) optionally subjecting the nucleotide sequence encoding the polypeptide selected in step c) to one or more repeated cycles of steps a)-c). In a further step the expressed polypeptides of step a) or c) can be conjugated to at least one non-polypeptide moiety.

Factor VII or VIIa - Like Molecules

Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.

Factor vii or viia polypeptide variants

Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse

Abuse resistant polyglycol-based pharmaceutical compositions are disclosed. The composition contains one or more polyglycols and one or more active substances and it is resistant to crushing, melting and/or extraction. Moreover, such compositions have the same or lower solubility in ethanolic-aqueous medium, i.e. they are not subject to ethanol-induced dose dumping effect.

Catheter system having disposable balloon

A disposable balloon catheter and corresponding catheter system are disclosed. In one embodiment, the catheter system comprises several components, such as: (a) an elongated catheter comprising a first outer diameter, a first proximal end and a first distal end; (b) an elongated balloon carrier having a second proximal end, a second distal end and a second outer diameter, the second proximal end of the carrier and the first distal end of the catheter being configured to permit the first distal end of the catheter to matingly engage the second proximal end of the carrier, the second outer diameter of the balloon carrier being similar to the first outer diameter of the catheter; and (c) a disposable balloon formed from an expandable and resilient biocompatible material, the balloon having a lumen disposed between a third proximal end and a third distal end thereof, the lumen having at least a third inside diameter. The second proximal end of the carrier and the first distal end of the catheter are preferably configured to permit the first distal end of the catheter to matingly engage the second proximal end of the carrier. In a preferred embodiment, the second outer diameter of the balloon carrier is similar to the first outer diameter of the catheter such that the second diameter of the carrier and the third diameter of the balloon permit the balloon first to be slideably mounted onto the balloon carrier and second to be slideably moved from the carrier onto the catheter when the second proximal end of the carrier is matingly or otherwise suitably engaged with the first distal end of the catheter.

A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease

Provided herein is a pharmaceutical composition comprising : (a) an effective amount of one or more of acetylcholinesterase inhibitor(s) or a pharmaceutically effective salt thereof; and (b) an effective amount of one or more NMDA-antagonist(s). Also provided is the use of the above composition for the manufacture of a medicament for the treatment of mild cognitive impairment or dementia.

Novel galactoside inhibitors of galectins

The present invention relates to a compound of the general formula (1). wherein A is selected from a group of formula 2. B is selected from a group of formula 3. The compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.

Polarization diversity image-reject homodyne receiver for directional radial velocity measurements in light detection and ranging (lidar) instruments

The present invention relates to an improved method and a LIDAR system comprising an emitter for emission of a coherent electromagnetic EM signal and a transmitting optical arrangement configured to transmit the electromagnetic signal towards a measurement area. By the method and system, detection of both the polarized and depolarized backscattered EM signal is obtained, whereby an improved signal-to-noise ratio is obtained.